Cyclic-di-GMP induces inflammation and acute lung injury through direct binding to MD2

Abstract

Background: Severe bacterial infections can trigger acute lung injury (ALI) and acute respiratory distress syndrome, with bacterial pathogen-associated molecular patterns (PAMPs) exacerbating the inflammatory response, particularly in COVID-19 patients. Cyclic-di-GMP (CDG), one of the PAMPs, is synthesized by various Gram-positve and Gram-negative bacteria. Previous studies mainly focused on the inflammatory responses triggered by intracellular bacteria-released CDG. However, how extracellular CDG, which is released by bacterial autolysis or rupture, activates the inflammatory response remains unclear.

Methods: The interaction between extracellular CDG and myeloid differentiation protein 2 (MD2) was investigated using in vivo and in vitro models. MD2 blockade was achieved using specific inhibitor and genetic knockout mice. Site-directed mutagenesis, co-immunoprecipitation, SPR and Bis-ANS displacement assays were used to identify the potential binding sites of MD2 on CDG.

Results: Our data show that extracellular CDG directly interacts with MD2, leading to activation of the TLR4 signalling pathway and lung injury. Specific inhibitors or genetic knockout of MD2 in mice significantly alleviated CDG-induced lung injury. Moreover, isoleucine residues at positions 80 and 94, along with phenylalanine at position 121, are essential for the binding of MD2 to CDG.

Conclusion: These results reveal that extracellular CDG induces lung injury through direct interaction with MD2 and activation of the TLR4 signalling pathway, providing valuable insights into bacteria-induced ALI mechanisms and new therapeutic approaches for the treatment of bacterial co-infection in COVID-19 patients.

Keywords

acute lung injury / COVID-19 / cyclic-di-GMP / MD2

References

[1] He Y-Q, Zhou C-C, Yu L-Y, et al. Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms. Pharmacol Res. 2021;163:105224.

[2] Liu C, Xiao K, Xie L. Advances in the use of exosomes for the treatment of ALI/ARDS. Front Immunol. 2022;13:971189.

[3] Fan EKY, Fan J. Regulation of alveolar macrophage death in acute lung inflammation. Respir Res. 2018;19(1):50.

[4] Zhu W, Wang M, Jin L, et al. Licochalcone A protects against LPS-induced inflammation and acute lung injury by directly binding with myeloid differentiation factor 2 (MD2). Br J Pharmacol. 2023;180(8):1114-1131.

[5] Collaborators G. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221-2248.

[6] Vidaur L, Eguibar I, Olazabal A, et al. Impact of antimicrobial stewardship in organisms causing nosocomial infection among COVID-19 critically ill adults. Eur J Intern Med. 2024;119:93-98.

[7] Gan Y, Zhang G, Sun H, Lyu X. Clinical characteristics and risk factors for bacterial co-infections in COVID-19 patients: a retrospective study. J Glob Antimicrob Resist. 2024.

[8] Naqvi I, Giroux N, Olson L, et al. DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. Biomaterials. 2022;283:121393.

[9] Schröder NWJ, Morath S, Alexander C, et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem. 2003;278(18):15587-15594.

[10] Bitto NJ, Cheng L, Johnston EL, et al. Staphylococcus aureus membrane vesicles contain immunostimulatory DNA, RNA and peptidoglycan that activate innate immune receptors and induce autophagy. J Extracell Vesicles. 2021;10(6):e12080.

[11] Wang F, Li Y, Yang C, et al. Mannan-binding lectin suppresses peptidoglycan-induced TLR2 activation and inflammatory responses. Mediators Inflamm. 2019;2019:1349784.

[12] Akahoshi DT, Bevins CL. Flagella at the host-microbe interface: key functions intersect with redundant responses. Front Immunol. 2022;13:828758.

[13] Almblad H, Randall TE, Liu F, et al. Bacterial cyclic diguanylate signaling networks sense temperature. Nat Commun. 2021;12(1):1986.

[14] de Moura Rodrigues D, Lacerda-Queiroz N, Couillin I, Riteau N. STING targeting in lung diseases. Cells. 2022;11(21).

[15] Couillin I, Riteau N. STING signaling and sterile inflammation. Front Immunol. 2021;12:753789.

[16] Parvatiyar K, Zhang Z, Teles RM, et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol. 2012;13(12):1155-1161.

[17] Oduro PK, Zheng X, Wei J, et al. The cGAS-STING signaling in cardiovascular and metabolic diseases: future novel target option for pharmacotherapy. Acta Pharm Sin B. 2022;12(1):50-75.

[18] Tian X, Liu C, Wang Z. The induction of inflammation by the cGAS-STING pathway in human dental pulp cells: a laboratory investigation. Int Endod J. 2022;55(1):54-63.

[19] Mcwhirter SM, Barbalat R, Monroe KM, et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med. 2009;206(9):1899-1911.

[20] Kumagai Y, Matsuo J, Hayakawa Y, Rikihisa Y. Cyclic di-GMP signaling regulates invasion by Ehrlichia chaffeensis of human monocytes. J Bacteriol. 2010;192(16):4122-4133.

[21] Sooreshjani MA, Gursoy UK, Aryal UK, Sintim HO. Proteomic analysis of RAW macrophages treated with cGAMP or c-di-GMP reveals differentially activated cellular pathways. RSC Adv. 2018;8(64):36840-36851.

[22] Wang M, Chaudhuri R, Ong WWS, Sintim HO. c-di-GMP induces COX-2 expression in macrophages in a STING-independent manner. ACS Chem Biol. 2021;16(9):1663-1670.

[23] Wu J, Li J, Cai Y, et al. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J Med Chem. 2011;54(23):8110-8123.

[24] Matute-Bello G, Downey G, Moore BB, et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011;44(5):725-738.

[25] Huang X, Xiu H, Zhang S, Zhang G. The role of macrophages in the pathogenesis of ALI/ARDS. Mediators Inflamm. 2018;2018:1264913.

[26] Wu Y, Yu X, Wang Y, et al. Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling. Acta Pharm Sin B. 2022;12(3):1198-1212.

[27] Zhao R, Wang L, Wang T, Xian P, Wang H, Long Q. Inhalation of MSC-EVs is a noninvasive strategy for ameliorating acute lung injury. J Control Release. 2022;345:214-230.

[28] Wang Y, Su L, Morin MD, et al. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci USA. 2016;113(7):E884-893.

[29] Rajaiah R, Perkins DJ, Ireland DDC, Vogel SN. CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance. Proc Natl Acad Sci USA. 2015;112(27):8391-8396.

[30] Wu J-J, Zhao L, Hu H-G, Li W-H, Li Y-M. Agonists and inhibitors of the STING pathway: potential agents for immunotherapy. Med Res Rev. 2020;40(3):1117-1141.

[31] Dejmek M, Šála M, Brazdova A, et al. Discovery of isonucleotidic CDNs as potent STING agonists with immunomodulatory potential. Structure. 2022;30(8):1146-1156. e11.

[32] Hu Q, Zhou Q, Xia X, et al. Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis. J Exp Clin Cancer Res. 2021;40(1):39.

[33] Subramanian H, Hashem T, Bahal D, Kammala AK, Thaxton K, Das R. Ruxolitinib ameliorates airway hyperresponsiveness and lung inflammation in a corticosteroid-resistant murine model of severe asthma. Front Immunol. 2021;12:786238.

[34] Cavagnero KJ, Badrani JH, et al. Cyclic-di-GMP induces STING-dependent ILC2 to ILC1 shift during innate type 2 lung inflammation. Front Immunol. 2021;12:618807.

[35] Nguyen N, Xu S, Lam TYW, Liao W, Wong WSF, Ge R. ISM1 suppresses LPS-induced acute lung injury and post-injury lung fibrosis in mice. Mol Med. 2022;28(1):72.

[36] Elmanfi S, Zhou J, Sintim HO, Könönen E, Gürsoy M, Gürsoy UK. Regulation of gingival epithelial cytokine response by bacterial cyclic dinucleotides. J Oral Microbiol. 2019;11(1):1538927.

[37] Elmanfi S, Sintim HO, Zhou J, Gürsoy M, Könönen E, Gürsoy UK. Activation of gingival fibroblasts by bacterial cyclic dinucleotides and lipopolysaccharide. Pathogens. 2020;9(10).

[38] Ding C, Song Z, Shen A, Chen T, Zhang Ao. Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway. Acta Pharm Sin B. 2020;10(12):2272-2298.

[39] Christensen MH, Jensen SB, Miettinen JJ, et al. HSV-1 ICP27 targets the TBK1-activated STING signalsome to inhibit virus-induced type I IFN expression. EMBO J. 2016;35(13):1385-1399.

[40] Chen Y-A, Shen Y-L, Hsia H-Y, Tiang Y-P, Sung T-L, Chen L-Y. Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway. Nat Struct Mol Biol. 2017;24(12):1124-1131.

[41] Haag SM, Gulen MF, Reymond L, et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559(7713):269-273.

[42] Li S, Hong Ze, Wang Z, et al. The cyclopeptide Astin C specifically inhibits the innate immune CDN sensor STING. Cell Rep. 2018;25(12):3405-3421. e7.

[43] Luo Wu, Yang Li-B, Qian C-C, et al. Flavokawain B alleviates LPS-induced acute lung injury via targeting myeloid differentiation factor 2. Acta Pharmacol Sin. 2022;43(7):1758-1768.

[44] Zhang Ya-Li, Zhang W-X, Yan J-Q, et al. Chalcone derivatives ameliorate lipopolysaccharide-induced acute lung injury and inflammation by targeting MD2. Acta Pharmacol Sin. 2022;43(1):76-85.

[45] Burdette DL, Monroe KM, Sotelo-Troha K, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478(7370):515-518.

[46] Jiang Y, Zhu Y, Liu Z-J, Ouyang S. The emerging roles of the DDX41 protein in immunity and diseases. Protein Cell. 2017;8(2):83-89.

[47] Moreno-García E, Puerta-Alcalde P, Letona L, et al. Bacterial co-infection at hospital admission in patients with COVID-19. Int J Infect Dis. 2022;118:197-202.

[48] Xia W, Shao J, Guo Yu, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020;55(5):1169-1174.

[49] Petruk G, Puthia M, Petrlova J, et al. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. J Mol Cell Biol. 2020;12(12):916-932.

[50] Zhao Y, Kuang M, Li J, et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 2021;31(7):818-820.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.